Tivic Health Systems Acquires Entolimod, Expanding Therapeutics Pipeline and Market Potential

Tivic Health Systems Expands Therapeutics Pipeline with Entolimod Acquisition

Tivic Health Systems, Inc. has made a significant leap in its transition from a direct-to-consumer model to a diversified therapeutics company by acquiring worldwide exclusive license rights for the Toll-like Receptor 5 (TLR5) agonist Entolimod™ from Statera Biopharma. This strategic acquisition is pivotal for Tivic, as it not only encompasses exclusive rights for Entolimod but also an option for five additional indications related to this compound and its derivative, Entalasta™. This move aligns with Tivic's ongoing commitment to developing innovative, non-invasive treatments aimed at addressing immune and autonomic dysregulation, further broadening its clinical pipeline.

Entolimod has garnered attention for its potential in treating acute radiation syndrome (ARS), a condition that can arise from exposure to high levels of radiation. The drug has undergone extensive scrutiny, with over 40 clinical trials demonstrating promising outcomes. Notably, it has received both Fast Track and Orphan Drug designations from the FDA, emphasizing its therapeutic potential for ARS. The global market for ARS is expected to surge to USD 5.2 billion by 2024, growing at an annual rate of 5% until 2031, with Statera positioned as a key player in this sector. The acquisition places Tivic Health in a strategic position to capitalize on this expanding market, leveraging its expertise in non-invasive therapies.

One standout feature of Entolimod is its impressive efficacy demonstrated in animal studies, where it has shown a three-fold increase in survival rates after a single dose administered 25 hours post-exposure to lethal radiation. The drug’s gastrointestinal protective qualities, coupled with a favorable safety profile, highlight its potential for clinical application. Jennifer Ernst, CEO of Tivic, emphasizes that this licensing agreement is a significant step towards enhancing their product offerings and providing innovative solutions for radiation-related illnesses. The collaboration with Statera not only benefits Tivic but also reflects a shared commitment to advancing Entolimod toward a Biologics License Application (BLA) filing and eventual FDA approval.

In addition to the potential of Entolimod, this acquisition marks a pivotal point in Tivic's evolution as it strategically diversifies its offerings within the biopharmaceutical landscape. The company’s focus on integrating TLR5 immunotherapy with its existing technologies promises to enhance their therapeutic strategies. Furthermore, Michael K. Handley, CEO of Statera, expresses optimism that this partnership will yield substantial value for both companies’ shareholders as they work together to bring Entolimod to the market. This venture not only signifies a growth opportunity for Tivic Health but also reinforces its commitment to addressing critical health challenges through innovative therapeutic solutions.